Oxford BioMedica (OXOA) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Retinostat | Age-Related Macular Degeneration | Phase I | Active Not Recruiting | A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration | Aug 31, 2012 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Retinostat | Phase I | Age-Related Macular Degeneration | Active Not Recruiting | A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration | Aug 31, 2012 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Oxford Biomedica (otc) (DE:OXOA) have in its pipeline
Oxford BioMedica DE:OXOA is currently developing the following drugs: Retinostat. These drug candidates are in various stages of clinical development as the company works toward FDA approval.